retatrutide triple agonist glp-1 gip glucagon ly3437943 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials GLP-1 receptor agonists are Quantity:90 CT (3 Bottles) Supplements

retatrutide triple agonist glp-1 gip glucagon ly3437943 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials GLP-1 receptor agonists are Quantity:90 CT (3 Bottles) Supplements

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal.

the trial that ultimately proved that he was onto something — showing that aspirin in heart attack victims cut vascular deaths by a fifth — didn’t run until 1988

Supplements

Quantity:90 CT (3 Bottles)

SGLT2i, sodium-glucose cotransporter 2 inhibitor